Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 9.5% in the 3rd quarter, Holdings Channel reports. The firm owned 38,850 shares of the biopharmaceutical company’s stock after buying an additional 3,358 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Intra-Cellular Therapies were worth $2,843,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ITCI. SG Americas Securities LLC lifted its position in shares of Intra-Cellular Therapies by 50.8% during the 1st quarter. SG Americas Securities LLC now owns 4,590 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 1,547 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Intra-Cellular Therapies by 9.8% during the first quarter. Sei Investments Co. now owns 128,311 shares of the biopharmaceutical company’s stock valued at $8,880,000 after purchasing an additional 11,488 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Intra-Cellular Therapies in the 1st quarter valued at $32,000. Russell Investments Group Ltd. increased its stake in Intra-Cellular Therapies by 232.0% in the 1st quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock worth $3,519,000 after purchasing an additional 35,528 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in Intra-Cellular Therapies by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 23,621 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 1,962 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on ITCI. Royal Bank of Canada raised their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. UBS Group cut their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. Morgan Stanley upped their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, JPMorgan Chase & Co. raised their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Intra-Cellular Therapies Price Performance

ITCI opened at $83.42 on Friday. The company has a market capitalization of $8.84 billion, a PE ratio of -95.88 and a beta of 0.97. The business has a 50-day moving average of $78.27 and a 200-day moving average of $74.29. Intra-Cellular Therapies, Inc. has a fifty-two week low of $54.17 and a fifty-two week high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. During the same quarter last year, the firm earned ($0.25) earnings per share. Intra-Cellular Therapies’s revenue was up 39.0% compared to the same quarter last year. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other news, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. The trade was a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 179,471 shares of company stock valued at $13,670,383. Insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.